{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:24:28Z","timestamp":1791617068652,"version":"4.3.4"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":1438,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Heart failure (HF) is a proinflammatory disease often associated with the onset of iron deficiency (ID). ID alters mitochondrial function, reducing the generation of cellular energy in skeletal muscle and cardiomyocytes. This study aimed to analyse the response of patients with HF to intravenous iron administration according to the type of HF: preserved ejection fraction (HFpEF) or reduced ejection fraction (HFrEF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We conducted a retrospective, single-centre study of 565 consecutive outpatients diagnosed with HF, recruited over 5 years, who were given intravenous ferric carboxymaltose (FCM) for the treatment of ID [defined as ferritin &amp;lt; 100 \u03bcg\/L or ferritin 100\u2013300 \u03bcg\/L with transferrin saturation (TSAT) &amp;lt; 20%]. Clinical, laboratory, and echocardiographic parameters were analysed before and after administration. After FCM administration, overall ferritin, TSAT, and haemoglobin levels increased up to 5-fold, 1.6-fold, and 1.1-fold, respectively, relative to baseline values in HF patients with reduced and preserved ejection fraction (P &amp;lt; 0.0001), with a greater increase in ferritin and TSAT in HFpEF patients. The left ventricular ejection fraction of the overall series improved by 8 percentage points in both types of HF (from 40% to 48%, P &amp;lt; 0.0001). The percentage of patients with normalization of right ventricular function increased by 6.9 points (from 74.1% to 81%) in HFpEF patients and by 6.4 points (from 53% to 59.4%) in the HFrEF subgroup (P &amp;lt; 0.0001). New York Heart Association functional status slightly improved, from a median of 2.4 (interquartile range, IQR: 2\u20132.7) to 1.9 (IQR: 1.5\u20132.5; P &amp;lt; 0.0001) after FCM in both types of HF. No changes were noted in plasma levels of liver enzymes, creatinine, or natriuretic peptide (P &amp;gt; 0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Intravenous iron administration appeared to improve ejection fraction and cardiac functional status in outpatients with ID and HF with both preserved and reduced ejection fraction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13753","type":"journal-article","created":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T01:40:49Z","timestamp":1640742049000},"page":"133-145","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Impact of Intravenous Ferric Carboxymaltose on Heart Failure with Preserved and Reduced Ejection Fraction"],"prefix":"10.1093","volume":"9","author":[{"given":"Raquel","family":"L\u00f3pez-Vilella","sequence":"first","affiliation":[{"name":"Heart Failure and Transplantation Unit, Hospital Universitario y Polit\u00e9cnico La Fe , Valencia ,","place":["Spain"]},{"name":"Department of Cardiology, Hospital Universitario y Polit\u00e9cnico La Fe , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Lozano-Edo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario y Polit\u00e9cnico La Fe , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Arenas Mart\u00edn","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario y Polit\u00e9cnico La Fe , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Jover-Pastor","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario y Polit\u00e9cnico La Fe , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryem","family":"Ezzitouny","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario y Polit\u00e9cnico La Fe , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Sorolla Romero","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario y Polit\u00e9cnico La Fe , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Calvo Asensio","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario y Polit\u00e9cnico La Fe , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Mart\u00ednez-Sol\u00e9","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario y Polit\u00e9cnico La Fe , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Guerrero Cervera","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario y Polit\u00e9cnico La Fe , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Carlos","family":"S\u00e1nchez Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario y Polit\u00e9cnico La Fe , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Donoso Trenado","sequence":"additional","affiliation":[{"name":"Heart Failure and Transplantation Unit, Hospital Universitario y Polit\u00e9cnico La Fe , Valencia ,","place":["Spain"]},{"name":"Department of Cardiology, Hospital Universitario y Polit\u00e9cnico La Fe , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"S\u00e1nchez-L\u00e1zaro","sequence":"additional","affiliation":[{"name":"Heart Failure and Transplantation Unit, Hospital Universitario y Polit\u00e9cnico La Fe , Valencia ,","place":["Spain"]},{"name":"Department of Cardiology, Hospital Universitario y Polit\u00e9cnico La Fe , Valencia ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Martinez Dolz","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario y Polit\u00e9cnico La Fe , Valencia ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Almenar Bonet","sequence":"additional","affiliation":[{"name":"Heart Failure and Transplantation Unit, Hospital Universitario y Polit\u00e9cnico La Fe , Valencia ,","place":["Spain"]},{"name":"Department of Cardiology, Hospital Universitario y Polit\u00e9cnico La Fe , Valencia ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Universidad de Valencia , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,28]]},"reference":[{"key":"2026012114183266000_ehf213753-bib-0001","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/164_2016_74","article-title":"Epidemiology of heart failure","volume":"243","author":"Orso","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"2026012114183266000_ehf213753-bib-0002","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00392-018-1344-x","article-title":"Iron deficiency in patients with heart failure with preserved ejection fraction and its association with reduced exercise capacity, muscle strength and quality of life","volume":"108","author":"Bekfani","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"2026012114183266000_ehf213753-bib-0003","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijcard.2015.11.178","article-title":"The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the Studies Investigating Co-morbidities Aggravating Heart Failure","volume":"205","author":"Ebner","year":"2016","journal-title":"Int J Cardiol"},{"key":"2026012114183266000_ehf213753-bib-0004","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2019-001012","article-title":"Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"6","author":"Beale","year":"2019","journal-title":"Open Heart"},{"key":"2026012114183266000_ehf213753-bib-0005","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/ehf2.12797","article-title":"Anaemia, iron deficiency and heart failure in 2020: facts and numbers","volume":"7","author":"Chopra","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114183266000_ehf213753-bib-0006","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/00015385.2017.1351239","article-title":"Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction","volume":"73","author":"Martens","year":"2018","journal-title":"Acta Cardiol"},{"key":"2026012114183266000_ehf213753-bib-0007","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10741-019-09815-z","article-title":"Iron deficiency as therapeutic target in heart failure: a translational approach","volume":"25","author":"Bakogiannis","year":"2020","journal-title":"Heart Fail Rev"},{"key":"2026012114183266000_ehf213753-bib-0008","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"2026012114183266000_ehf213753-bib-0009","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"key":"2026012114183266000_ehf213753-bib-0010","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012114183266000_ehf213753-bib-0011","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014254","article-title":"Noninvasive imaging estimation of myocardial iron repletion following administration of intravenous iron: the Myocardial-IRON trial","volume":"9","author":"N\u00fa\u00f1ez","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026012114183266000_ehf213753-bib-0012","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1002\/ehf2.13053","article-title":"Short-term changes in left and right systolic function following ferric carboxymaltose: a substudy of the Myocardial-IRON trial","volume":"7","author":"Santas","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114183266000_ehf213753-bib-0013","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"2026012114183266000_ehf213753-bib-0014","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.rce.2016.08.001","article-title":"Documento de consenso de la Sociedad Espa\u00f1ola de Cardiolog\u00eda y la Sociedad Espa\u00f1ola de Medicina Interna sobre el diagn\u00f3stico y tratamiento del d\u00e9ficit de hierro en la insuficiencia card\u00edaca","volume":"217","author":"Manito","year":"2017","journal-title":"Rev Clin Esp"},{"key":"2026012114183266000_ehf213753-bib-0015","volume-title":"Ferinject\u00ae, 50 mg\/ml soluci\u00f3n inyectable y para perfusi\u00f3n","author":"Pharma","year":"2020"},{"key":"2026012114183266000_ehf213753-bib-0016","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012114183266000_ehf213753-bib-0017","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann Intern Med"},{"key":"2026012114183266000_ehf213753-bib-0018","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2026012114183266000_ehf213753-bib-0019","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"key":"2026012114183266000_ehf213753-bib-0020","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.hfc.2019.08.003","article-title":"Chronic obstructive pulmonary disease and heart failure","volume":"16","author":"Pellicori","year":"2020","journal-title":"Heart Fail Clin"},{"key":"2026012114183266000_ehf213753-bib-0021","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cphy.c140046","volume-title":"Comprehensive Physiology","author":"Gardner","year":"2015"},{"key":"2026012114183266000_ehf213753-bib-0022","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nrcardio.2016.25","article-title":"Epidemiology and aetiology of heart failure","volume":"13","author":"Ziaeian","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"2026012114183266000_ehf213753-bib-0023","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"2026012114183266000_ehf213753-bib-0024","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1056\/NEJMoa051530","article-title":"Outcome of heart failure with preserved ejection fraction in a population-based study","volume":"355","author":"Bhatia","year":"2006","journal-title":"N Engl J Med"},{"key":"2026012114183266000_ehf213753-bib-0025","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N Engl J Med"},{"key":"2026012114183266000_ehf213753-bib-0026","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/ejhf.327","article-title":"Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response","volume":"17","author":"Kao","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026012114183266000_ehf213753-bib-0027","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1161\/CIRCULATIONAHA.114.010637","article-title":"Phenomapping for novel classification of heart failure with preserved ejection fraction","volume":"131","author":"Shah","year":"2015","journal-title":"Circulation"},{"key":"2026012114183266000_ehf213753-bib-0028","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation"},{"key":"2026012114183266000_ehf213753-bib-0029","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1053\/ajkd.2001.28587","article-title":"Intravenous iron sucrose: establishing a safe dose","volume":"38","author":"Chandler","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"2026012114183266000_ehf213753-bib-0030","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40265-014-0332-3","article-title":"Ferric carboxymaltose: a review of its use in iron deficiency","volume":"75","author":"Keating","year":"2015","journal-title":"Drugs"},{"key":"2026012114183266000_ehf213753-bib-0031","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1055\/s-0031-1296299","article-title":"The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose","volume":"60","author":"Funk","year":"2011","journal-title":"Arzneimittelforschung"},{"key":"2026012114183266000_ehf213753-bib-0032","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10741-018-9738-4","article-title":"Structural and functional abnormalities in iron-depleted heart","volume":"24","author":"Kobak","year":"2019","journal-title":"Heart Fail Rev"},{"key":"2026012114183266000_ehf213753-bib-0033","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1540-8175.2011.01532.x","article-title":"Tissue Doppler and strain rate imaging detect improvement of myocardial function in iron deficient patients with congestive heart failure after iron replacement therapy","volume":"29","author":"Gaber","year":"2012","journal-title":"Echocardiography"},{"key":"2026012114183266000_ehf213753-bib-0034","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/ehf2.12101","article-title":"Left ventricular ejection fraction recovery in patients with heart failure treated with intravenous iron: a pilot study","volume":"3","author":"N\u00fa\u00f1ez","year":"2016","journal-title":"ESC Heart Fail"},{"key":"2026012114183266000_ehf213753-bib-0035","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijcard.2016.03.039","article-title":"Intravenous iron sucrose reverses anemia-induced cardiac remodeling, prevents myocardial fibrosis, and improves cardiac function by attenuating oxidative\/nitrosative stress and inflammation","volume":"212","author":"Toblli","year":"2016","journal-title":"Int J Cardiol"},{"key":"2026012114183266000_ehf213753-bib-0036","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijcard.2011.08.006","article-title":"Myocardial iron homeostasis in advanced chronic heart failure patients","volume":"159","author":"Leszek","year":"2012","journal-title":"Int J Cardiol"},{"key":"2026012114183266000_ehf213753-bib-0037","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jacc.2007.07.029","article-title":"Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency","volume":"50","author":"Toblli","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026012114183266000_ehf213753-bib-0038","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency\u2020","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012114183266000_ehf213753-bib-0039","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014254","article-title":"Noninvasive imaging estimation of myocardial iron repletion following administration of intravenous iron: the Myocardial-IRON trial","volume":"9","author":"N\u00fa\u00f1ez","year":"2020","journal-title":"J Am Heart Assoc"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13753","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13753","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/1\/133\/65375007\/eschf_9_1_133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/1\/133\/65375007\/eschf_9_1_133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:22:00Z","timestamp":1769023320000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/9\/1\/133\/8326361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,28]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,28]]},"published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13753","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2]]},"published":{"date-parts":[[2021,12,28]]},"assertion":[{"value":"2021-03-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}